{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092262","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.531670+00:00","generated_at":"2026-05-31T11:38:48.891162+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"EyePoint reports Q2 net loss of $30.8M; cash runway through DURAVYU Phase 3 topline in 2026","bullets":["Net loss $30.8M ($0.58/sh) vs $22.9M loss ($0.61/sh) in Q2 2023; total net revenue $9.5M.","Cash and investments $280.2M at June 30, 2024; expected to fund operations through Phase 3 wet AMD topline data in 2026.","Phase 3 LUGANO wet AMD trial on track for first patient dosing in 2024; LUCIA trial to follow shortly.","Positive 12-month DAVIO 2 data: DURAVYU non-inferior to aflibercept in visual acuity; majority supplement-free.","Phase 2 VERONA (DME) fully enrolled; topline data anticipated Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092262","json":"https://secwatch.observer/filing/0000950170-24-092262.json","markdown":"https://secwatch.observer/filing/0000950170-24-092262.md","text":"https://secwatch.observer/filing/0000950170-24-092262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024092262/0000950170-24-092262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024092262/eypt-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:38:48.891162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}